Nuvalent’s Promising Pipeline and Strategic Advancements Justify Buy Rating
Analyst Etzer Darout of BMO Capital maintained a Buy rating on Nuvalent (NUVL – Research Report), boosting the price target to $134.00.
Business Insider1d
Terns Pharmaceuticals: Promising Clinical Developments and Strong Financial Position Justify Buy Rating
Darout covers the Healthcare sector, focusing on stocks such as C4 Therapeutics, AstraZeneca, and Terns Pharmaceuticals. In another report released today, JMP Securities also maintained a Buy rating ...